RESEARCH PEPTIDE FUNDAMENTALS
What the Evidence Actually Shows, Not What the Marketing Implies
A rigorously skeptical reading desk on four research peptides — ipamorelin, PT-141, semaglutide, and tirzepatide — built around peptides as biologics: how they differ from small-molecule drugs, and how unevenly their evidence bases have matured.
Ipamorelin
A selective growth-hormone secretagogue with a striking evidence gap: its only human trial missed its primary endpoint.
Read the evidence →
PT-141
An FDA-approved melanocortin agonist for one narrow indication — and a much larger, mostly off-label, mostly anecdotal footprint beyond it.
Read the evidence →
Semaglutide
The GLP-1 agonist with the deepest trial record on this desk — and the one that lost, decisively, its own head-to-head matchup.
Read the evidence →
Tirzepatide
A dual-receptor agonist backed by large randomized trials, including the one that beat semaglutide outright.
Read the evidence →The short version
Peptide Biologicals reads four research peptides the way a skeptical reviewer reads a manuscript: what is the claim, what actually supports it, and what is still missing? The four compounds covered here — ipamorelin, PT-141, semaglutide, and tirzepatide — are all peptides, meaning short chains of amino acids, which puts them in a different category from ordinary pill-form drugs (called small molecules). That distinction matters more than most marketing acknowledges: peptides usually cannot survive a trip through the stomach intact, so most are injected, and the gap between animal data and confirmed human results is often wider than it first appears.
Some of the four compounds here have deep, multi-thousand-person clinical trial programs behind them and current FDA approval for broad use. At least one has a single human trial to its name — and that trial missed its main goal. This site sets out, compound by compound, which is which, with citations, and without inflating what a single study or a preclinical model can actually support.
Peptides as biologics: why size and shape matter
The organizing idea of this desk is that peptides are biologics, not small molecules, and that difference shapes almost everything else on these pages. A small-molecule drug — aspirin, for instance — is a compact, chemically stable structure that can often survive digestion and cross cell membranes on its own. A peptide is a chain of amino acids: bigger, floppier, and built out of the exact same chemical bonds that digestive enzymes exist to break. Left unmodified, a natural peptide hormone circulating in blood is often destroyed within minutes.
Every compound on this desk has been chemically re-engineered to survive longer than nature intended, and the specific engineering trick differs by molecule. Ipamorelin substitutes an artificial amino acid (Aib) and mirror-image D-amino acids into its five-residue chain to block the enzymes that would otherwise cut it apart. PT-141 (bremelanotide) closes its structure into a stabilized ring with a lactam bridge. Semaglutide and tirzepatide both attach a fatty acid "arm" to a lysine side chain, which lets the peptide cling to a blood protein instead of being filtered out by the kidneys, stretching a natural hormone's few-minute lifespan out to roughly a week. None of these tricks are available to a conventional pill; they are specifically biologic solutions to a biologic problem, which is exactly why nearly everything on this desk is given by injection rather than swallowed.
How this desk reads the evidence
This desk applies one standard evenly across all four compounds, regardless of how well-known or well-marketed each one is: a finding is described at the strength of the study that produced it, not at the strength of the claim built on top of it afterward. A single rat study is reported as a single rat study. A finding from a related, but different, molecule in the same drug class is labeled as such rather than folded silently into the target compound's own record. A trial that missed its primary endpoint is reported as having missed its primary endpoint, not quietly omitted.
Community-reported effects — the sleep changes, the recovery claims, the mood shifts people describe in forums and clinic blogs — are real reports, and they appear on every compound page here, but they are always labeled as anecdotal and never treated as a substitute for a controlled trial. Where a claim rests on a single study, or on preclinical data only, this desk says so plainly rather than letting repetition across marketing copy stand in for replication in the literature.
Four peptides, four different evidence ladders
Laid side by side, the four compounds on this desk occupy strikingly different rungs of an evidence ladder. Ipamorelin has excellent preclinical characterization and almost no confirmed human benefit — its one placebo-controlled human trial did not meet its primary endpoint. PT-141 has genuinely solid Phase 3 evidence, but for a single, narrow, FDA-approved indication that a much larger body of off-label use has since grown well beyond. Semaglutide carries the deepest and broadest trial record of the four, across diabetes, weight, cardiovascular, and kidney outcomes — and yet, in the one trial built to compare it directly against a rival, it lost. Tirzepatide is the newest entrant and, by that same head-to-head measure, the best-performing single molecule on this desk, though real open questions remain about its exact mechanism and its very long-term safety record.
Each compound gets its own page below, walking through what it is structurally, how it works, what its research record actually shows, and what is reported anecdotally versus cited from the clinical literature. The comparison page lines up all four side by side on the dimensions that matter most to a skeptical read.